Johnson & Johnson Says TAR-200 Monotherapy Shows Greater Than 80% Complete Response Rate In Patients With High-Risk Non-Muscle-Invasive Bladder Cancer; New Data From Phase 2b Sunrise-1 Study Show Rapid Achievement Of Complete Response With 98% Achieving A CR Within 12 Weeks
Portfolio Pulse from Benzinga Newsdesk
Johnson & Johnson announced that its TAR-200 monotherapy has shown a greater than 80% complete response rate in patients with high-risk non-muscle-invasive bladder cancer. The Phase 2b Sunrise-1 study revealed that 98% of patients achieved a complete response within 12 weeks.
May 03, 2024 | 3:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Johnson & Johnson's TAR-200 monotherapy demonstrates significant efficacy in treating high-risk non-muscle-invasive bladder cancer, with a high complete response rate.
The positive results from the Phase 2b Sunrise-1 study of TAR-200 in treating bladder cancer are likely to have a positive impact on Johnson & Johnson's stock price in the short term. The high efficacy rate and rapid achievement of complete response in a significant percentage of patients highlight the potential of TAR-200 as a leading treatment option. This could lead to increased investor confidence in J&J's pipeline of innovative treatments and potentially boost its stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100